Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation

Jonathan C. Yau, Meletios A. Dimopoulos, Susan D. Huan, Jeffrey J. Tarrand, Verneeda Spencer, Gary Spitzer, Carole M. Meneghetti, Ralph O. Wallerstein, Borje S. Andersson, C. Frederick LeMaistre

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Abstract: Cytomegalovirus (CMV) infection is one of the most common causes of morbidity and mortality after allogeneic marrow transplantation. We studied 14 consecutive CMV‐seropositive patients adding ganciclovir (2.5 mg/kg i.v. every 8 hours for 7 days prior to transplant and 6 mg/kg three times a week after neutrophils became > 0.5 times 109/1 and the patients were platelet transfusion‐independent until d 70) to our previous prophylaxis regimen which consisted of intravenous immunoglobulin and acyclovir. The result was compared with 30 consecutive patients whom we studied with our previous regimen. The addition of ganciclovir did not cause any extra toxicities. The incidence of interstitial pneumonitis and cumulative probability of CMV excretion in the first 100 d post‐transplantation was significantly reduced (p = 0.038 and p = 0.035 respectively). The result shows that addition of ganciclovir significantly decreased the incidence of CMV infection in the early post‐transplantation period.

Original languageEnglish (US)
Pages (from-to)371-376
Number of pages6
JournalEuropean Journal of Haematology
Volume47
Issue number5
DOIs
StatePublished - Nov 1991

Keywords

  • cytomegalovirus
  • ganciclovir
  • marrow transplantation
  • prophylaxis

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation'. Together they form a unique fingerprint.

Cite this